Recent filings confirm that Samira Shaikhly, Chief People Officer at Septerna, Inc. (NASDAQ:SEPN), sold 11,798 shares of the company’s common stock on May 26, 2026. The total proceeds from this transaction amounted to $354,656. During the sale period, the executed prices for these shares ranged between $30.00 and $30.24, resulting in a weighted average price of $30.0607 per share.
It is noted that this stock disposition was structured under a Rule 10b5-1 sales plan, which Ms. Shaikhly initially adopted on October 31, 2025. This pre-arranged plan governs the timing and execution of the sale, providing context to the transaction.
The report highlights that this activity occurred while Septerna stock was trading near its 52-week high of $32.63. This valuation reflects a significant upward trajectory for the company's shares, showing an impressive 219% return over the past year. From a financial health perspective, analysis provided by InvestingPro assigned SEPN a 'GREAT' rating with a score of 3.41.
Previous Transactions and Holdings
Prior to executing the sale detailed above, Ms. Shaikhly had acquired an additional 11,798 shares of Septerna common stock on the same date through the exercise of existing stock options. These newly acquired shares were purchased at an exercise price of $6.81 per share, totaling $80,344.
These exercised stock options were part of a larger grant agreement. The vesting and exercisability schedule stipulated that 1/48th of the total shares would vest and become available in substantially equal monthly installments on each monthly anniversary of October 28, 2024. This continued access to company equity is contingent upon Ms. Shaikhly maintaining her continuous service with Septerna.
Following all reported transactions, Ms. Shaikhly's direct personal holding of Septerna common stock stands at 793 shares.
Clinical Development and Analyst Sentiment
Beyond executive trading activity, the company has generated significant news regarding its clinical development progress, drawing attention from various industry analysts. H.C. Wainwright recently reiterated a Buy rating for Septerna, setting a price target of $40. This positive reassessment followed encouraging outcomes reported from a Phase 1 trial involving SEP-631, a drug candidate designed to treat chronic spontaneous urticaria.
The findings from the trial indicated that the drug was both effective and well-tolerated by participants. In response to these results, Septerna has plans to initiate a subsequent Phase 2b trial in 2026. Furthermore, the company advanced another key program, beginning participant dosing for SEP-479, which targets hypoparathyroidism. This ongoing study is currently involving up to 150 volunteers.
Analyst Commentary and Pipeline Milestones
The positive momentum is corroborated by external financial assessments. Truist Securities elevated its price target for Septerna to $35 while maintaining a Buy rating, citing that the company’s clinical trial timelines continue to progress as anticipated. Specifically regarding SEP-479, the necessary IND-enabling studies have been successfully completed, with the initiation of a Phase 1 trial projected for early 2026.
Adding further confidence to its valuation, Cantor Fitzgerald reiterated an Overweight rating and established a $60 price target. This high valuation reflects strong conviction in Septerna’s overall platform value and ongoing drug development capabilities. These multiple reports underscore the company’s sustained advancement across its various drug pipelines and the generally positive outlook presented by market analysts.